Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

639.50DKK
31 Jul 2015
Change (% chg)

kr.1.50 (+0.24%)
Prev Close
kr.638.00
Open
kr.638.00
Day's High
kr.654.50
Day's Low
kr.623.00
Volume
282,248
Avg. Vol
307,740
52-wk High
kr.693.50
52-wk Low
kr.212.40

GEN.CO

Chart for GEN.CO

About

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in... (more)

Overall

Beta: 1.02
Market Cap(Mil.): kr.37,549.84
Shares Outstanding(Mil.): 58.72
Dividend: --
Yield (%): --

Financials

  GEN.CO Industry Sector
P/E (TTM): 89.39 408.24 40.68
EPS (TTM): 7.15 -- --
ROI: 18.59 -5.70 15.78
ROE: 19.30 -5.72 16.82
Search Stocks

Genmab, Novartis leukemia drug Arzerra filed for European approval

COPENHAGEN - Novartis submitted an application to the European Medicines Agency (EMA) for the use of ofatumumab, branded as Arzerra, as maintenance therapy for patients with relapsed chronic lymphocytic leukemia, its co-developer Genmab said. 

08 Jul 2015

Genmab shares rise on cancer drug's FDA licence application

COPENHAGEN, June 8 - Shares in Genmab rose almost 3 percent on Monday after partner Johnson and Johnson's announcement late on Friday that the companies have applied to U.S. authorities for a licence to market their blood cancer drug daratumumab.

08 Jun 2015

BRIEF-Genmab says Gilead submits new drug application to U.S. FDA

* Says Gilead has submitted a supplemental new drug application with the U.S. Food and Drug Administration to include data from a Phase 3 study

01 Jun 2015

BRIEF-Genmab teams up with BioNTech on DuoBody tech platform

Enters Commercial DuoBody Technology Agreement with BioNTech in Field of Immuno-oncology

19 May 2015

BRIEF-Genmab expects to book DKK 22 million for Arzerra royalties

* Says worldwide net sales of Arzerra in Q1 2015 totaled GBP 11.1 million

06 May 2015

BRIEF-Genmab reach $10 mln milestone in Johnson & Johnson collaboration

* Says achieves 10 million dollar milestone in daratumumab collaboration with Janssen, a pharmaceutical company of Johnson & Johnson

16 Apr 2015

BRIEF-Genmab acquires antibody assets from IDD biotech

COPENHAGEN, March 18 - Genmab A/S : * Acquires antibody assets from idd biotech * Says pays upfront of EUR 2.5 million Source text for Eikon:

18 Mar 2015

Genmab reports 2014 op profit above guidance

March 2 - Danish biotech firm Genmab on Monday reported 2014 operating income (EBIT) above its own guidance.

02 Mar 2015

BRIEF-GSK agrees sale of Genmab stake for 194 mln stg

* Successfully agreed sale of 4,471,202 shares in Genmab, which represents GSK's entire shareholding of about 7.9 percent of share capital of genmab

05 Feb 2015

Deals of the day- Mergers and acquisitions

Feb 4 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:

04 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Wright Reports
$75.00
Provider : Reuters Investment Profile
$20.00
Provider : ValuEngine, Inc.
$49.00
Provider : ValuEngine, Inc.
$25.00
Provider : ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks